Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa

NCT01693029 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

435

Enrollment

INDUSTRY

Sponsor class

Conditions

Anemia
Chronic Kidney Disease (CKD)

Interventions

DRUG: HX575 epoetin alfa
DRUG: US-licensed epoetin alfa

Sponsor

Sandoz